GSK has unveiled a $2.2bn deal to acquire Californian biotech RAPT Therapeutics, gaining rights to ozureprubart (Ozu), a long-acting drug in development to protect against severe food allergies. It is the first large deal announced by GSK’s new chief executive, Luke Miels, who took the reins at the